Human papillomavirus vaccination and all-cause morbidity in adolescent girls: a cohort study of absence from school due to illness

Abstract Background A growing body of evidence supports the safety of the human papillomavirus (HPV) vaccines. However, concerns about autonomic dysfunction syndromes and non-specific symptoms continue to linger. These conditions are not easily captured by traditional diagnostic classification schemes and call for innovative approaches to the study of vaccine safety which take more general measures of all-cause morbidity into account. Methods Taking advantage of the unique Danish registers, including regional registration of absence from school, we conducted a cohort study of 14 068 adolescent Danish girls attending 5th through 9th grade in public schools in the municipality of Copenhagen during 1 August 2013–23 January 2018. We obtained time-varying HPV vaccination status and demographic information from nationwide registers. Using Poisson regression with random effects, we estimated rate ratios (RRs) of absence due to illness, comparing HPV-vaccinated girls with unvaccinated girls with adjustment for grade, season, calendar period, demographic factors and random effects at the individual, class and school levels. Results Our study included 6 206 188 school days with 213 221 days of absence from school due to illness (absence rate, 3.4%). Comparing absence rates due to illness in HPV-vaccinated and unvaccinated girls yielded an adjusted RR of 1.00 (95% confidence interval [CI], 0.98–1.03). Conclusions Our study provides an important and novel contribution to HPV vaccine safety. Using absence from school records, we were able to address important safety concerns without relying on medical diagnoses. We conclude that HPV vaccination does not increase the risk of morbidity in any manner that manifests as absence from school due to illness.

[1]  K. Mølbak,et al.  A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women, September 2009 to August 2017 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  H. D. de Melker,et al.  No evidence found for an increased risk of long-term fatigue following human papillomavirus vaccination of adolescent girls. , 2018, Vaccine.

[3]  J. Ollgren,et al.  The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. , 2018, Vaccine.

[4]  H. Whitaker,et al.  Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study , 2018, Canadian Medical Association Journal.

[5]  L. Petersen,et al.  Childhood Infections and Subsequent School Achievement Among 598,553 Danish Children , 2017, The Pediatric infectious disease journal.

[6]  T. Shimabukuro,et al.  Reports of Postural Orthostatic Tachycardia Syndrome After Human Papillomavirus Vaccination in the Vaccine Adverse Event Reporting System. , 2017, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[7]  P. Magnus,et al.  HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway. , 2017, Vaccine.

[8]  M. Arbyn,et al.  Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. , 2013, The Cochrane database of systematic reviews.

[9]  P. Sparén,et al.  Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study , 2013, BMJ.

[10]  W. Stroup Generalized Linear Mixed Models: Modern Concepts, Methods and Applications , 2012 .

[11]  K. Mølbak,et al.  The Danish vaccination register. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  A. Hoosen,et al.  Human papillomavirus (HPV) vaccines , 2012 .

[13]  C. Pedersen,et al.  The Danish Civil Registration System , 2011, Scandinavian journal of public health.

[14]  N. Nielsen,et al.  Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events. , 2009, Vaccine.

[15]  C. Siegrist Autoimmune diseases after adolescent or adult immunization: What should we expect? , 2007, Canadian Medical Association Journal.

[16]  C. Dolea,et al.  World Health Organization , 1949, International Organization.